Drug Trial Radar · NCT01346592
Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age
Last checked: Nov 20, 2026Latest source record: Mar 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,104
Actual
Start
Apr 2011
Primary completion
Jul 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- Novartis VaccinesNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 3, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 months, up to 72 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Study Aims to Evaluate the Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to \< 72 Months of Age.
Conditions
- Influenza Disease
Interventions
Trivalent split influenza vaccine (TIV)Biological
MF59-adjuvanted trivalent influenza vaccine (aTIV)Biological
Licensed comparator trivalent split influenza vaccine (comparator TIV)Biological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous StrainsTime frame: Day 1, Day 50
- Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titers Against Homologous StrainsTime frame: Day 50
- Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains (6 to <36 Months)Time frame: Day 1, Day 50
- Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects 6 to <36 Months of AgeTime frame: Day 50
Locations
34 sites in 5 countries. Site status is shown where the registry gives one.
401 Paideia Jeronimo Salguero 2835 Piso 1
Buenos Aires, Argentina
402 Hospital de Ninos Gallo 130
Buenos Aires, Argentina
403 Instituto Medico Rio Cuarto Hipolito Yrigoyen 1020
Córdoba, Argentina
405 Hospital Pediatrico Nino Jesus Castro Barros 650
Córdoba, Argentina
406 Hospital Nostra Senora de la Misericordia Belgrano 1500
Córdoba, Argentina
407 Centro Pediatrico Caballito Directorio 1658
Cuidad Automa de Beunos Aires, Argentina
408 Centro de Salud 31 Serpa y Republica del Libano
Mendoza, Argentina
409 Centro de Salud 16 Alpatacal y Chile
Villa Nueva, Argentina
206 Vaccine and Immunology Research Trials Unit University Department of Paediatrics 2nd floor Clarence Reiger Bldg Womens and Childrens Hospital
Adelaide, Australia
201 Royal Children Hospital Department of Respiratory Medicine
Herston, Australia
205 Vaccine and Immunisation Research Group Murdoch Childrens Research Institute School Of Population Health
Level 5 207 Bouverie Saint, Australia
202 Sydney Children Hospital Department of Immunology and Infectious Diseases
Randwick, Australia
204 National Centre for Immunisation Research and Surveillance Kids Research Institute The Childrens Hospital at Westmead
Westmead, Australia
502 Hospital Clinico Pontificia Universidad Catolica de Chile Marcoleta 357
Santiago, Chile
503 Clinica Tabancura Av Tabancura 1185
Santiago, Chile
111 DLSHI deCastro De La Salle Health Sciences Institute DBB B Dasmarinas
Cavite, Philippines
106 Research Institute for Tropical Medicine Alabang Muntinlupa
City of Muntinlupa, Philippines
108 RITM Research Institute for Tropical Medicine Department of Health Compound FILINVEST Corporate City Alabang
City of Muntinlupa, Philippines
109 De La Salle Health Sciences Institute
Dbbb Dasmarinas Cavite, Philippines
110 De La Salle Health Sciences Institute
Dbbb Dasmarinas Cavite, Philippines
103 Philippine General Hospital Taft Avenue
Manila, Philippines
107 Philippine General Hospital Taft Avenue
Manila, Philippines
112 PGH Lim Philippine General Hospital Taft Avenue
Manila, Philippines
114 Philippine General Hospital Taft Avenue
Manila, Philippines
105 Mary Chiles General Hospital 667 Gastambide St Sampaloc Manila
Manila, Philippines
102 University of the East Ramon Magsaysay Memorial 64 Aurora Boulevard Barangay Dona Imelda
Quezon, Philippines
101 Philippine Childrens Medical Center Quezon Avenue cor Agham Road Quezon City
Quezon City, Philippines
104 Philippine Childrens Medical Center Quezon Avenue cor Agham Road Quezon City
Quezon City, Philippines
113 Philippine Childrens Medical Center Quezon Avenue cor Agham Road Quezon City
Quezon City, Philippines
305 Worthwhile Clinical Trials Lakeview Hospital 1 Mowbray Avenue
Benoni, South Africa
304 Newgate Centre Suite 3
Johannesburg, South Africa
303 Emmed Research
Pretoria, South Africa
301 Perinatal HIV Research Unit, Baragwanath Hospital
Soweto, South Africa
302 Soweto Clinical Research
Soweto, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.